Abu Dhabi’s Mubadala Investment Company, through its unit Kelix Bio, has finalized the acquisition of DiabTec, a subsidiary of Julphar. This move marks a significant step in strengthening Mubadala’s biologicals portfolio and advancing biomanufacturing in the MENA region.

DiabTec’s advanced facility, equipped with 20,000-litre drug substance reactors and a dedicated cartridge fill-finish facility for drug products, meets stringent EU and US FDA standards. It is the first of its kind in the GCC, making it a unique asset for local and regional pharmaceutical production.

Mubadala highlighted that the acquisition aligns with its responsible investing strategy, addressing global healthcare challenges such as diabetes and the increasing demand for insulin analogues and GLP-1 products. By focusing on local manufacturing, the company aims to enhance the UAE’s life sciences sector and contribute to a more stable global supply chain for essential diabetes treatments.

Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform, described the deal as a “significant milestone” that reinforces the UAE’s position in the global life sciences ecosystem. According to *Zawya*, he emphasized that this investment supports global health outcomes while growing the UAE’s pharmaceutical capabilities.

Julphar’s Chairman, Sheikh Saqer Bin Humaid Al Qasimi, said the sale aligns with the company’s strategy to divest non-core assets while supporting Mubadala’s efforts to expand the UAE’s pharmaceutical manufacturing sector.

This acquisition reflects Mubadala’s broader commitment to advancing healthcare innovation and ensuring reliable access to essential medicines like insulin analogues.